In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.
Lori Wirth, MD
Advertisement
Articles by Lori Wirth, MD
Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.
Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.
Advertisement
Latest Updated Articles
Presentation and Disease Course of Differentiated Thyroid CancerPublished: March 30th 2022 | Updated:
- Frontline Treatment Options for RAI-refractory DTC
Published: April 8th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
5
